Warning: The NCBI web site requires JavaScript to function. more...
An official website of the United States government
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.
SPR (BCL6), Ontario institute for cancer research
Assay data:1 Active, 1 Activity ≤ 1 µM, 2 Tested
SummaryCompounds, ActiveCompounds, activity ≤ 1 µMRelated BioAssays by Target
BCL6 protein degradation in SU-DHL-4 cells
Assay data:1 Active, 2 Activity ≤ 1 µM, 3 Tested
BCL6::NCOR LUMIER in cells
Assay data:2 Active, 2 Activity ≤ 1 µM, 2 Tested
BCL6:BCOR ULight TR-FRET
Assay data:2 Active, 2 Activity ≤ 1 µM, 3 Tested
Inhibition of BCL6 (unknown origin) stably expressed in human SU-DHL-4 cells incubated for 2 days by luminescence based microplate reader analysis
Assay data:33 Active, 27 Activity ≤ 1 µM, 34 Tested
SummaryCompounds, ActiveCompounds, activity ≤ 1 µMPubMed CitationRelated BioAssays by Target
Binding affinity to BCL6 BTB domain (unknown origin) assessed as dissociation constant by surface plasmon resonance assay
Assay data:35 Active, 3 Activity ≤ 1 nM, 34 Activity ≤ 1 µM, 52 Tested
Displacement of labelled SMRT peptide from BCL6 BTB domain (unknown origin) by fluorescence polarization assay
Assay data:3 Active, 2 Activity ≤ 1 µM, 21 Tested
Inhibition of human BCL6 BTP domain
Assay data:1 Active, 3 Activity ≤ 1 µM, 4 Tested
Induction of degradation of human BCL6 BTP domain by immunofluorescence (IF) staining assay
Inhibition of human BCL6 BTP domain measured by fluorescence polarization assay
Assay data:5 Tested
SummaryPubMed CitationRelated BioAssays by Target
Irreversible inhibition of human BCL6 BTP domain measured by TR-FRET assay
Reversible inhibition of human BCL6 BTP domain measured by TR-FRET assay
Assay data:1 Active, 1 Activity ≤ 1 µM, 1 Tested
Binding affinity to human BCL6 BTP domain assessed as dissociation constant by biolayer interferometry assay
Assay data:3 Active, 1 Activity ≤ 1 µM, 3 Tested
Inhibition of BCL6/SMRT protein protein interaction (unknown origin) by TR-FRET assay
Inhibition of human BCL6 BTP domain measured by cell reporter assay
Assay data:7 Active, 3 Activity ≤ 1 µM, 7 Tested
Inhibition of human BCL6 BTP domain measured by TR-FRET assay
Assay data:14 Active, 13 Activity ≤ 1 µM, 16 Tested
Binding affinity to human BCL6 BTP domain assessed as dissociation constant by SPR assay
Assay data:5 Active, 1 Activity ≤ 1 nM, 4 Activity ≤ 1 µM, 11 Tested
Inhibition of human BCL6 BTP domain by ELISA assay
Assay data:6 Active, 1 Activity ≤ 1 nM, 5 Activity ≤ 1 µM, 9 Tested
Surface Plasmon Resonance (SPR) assay from OICR from Article : "Discovery of OICR12694: A Novel, Potent, Selective, and Orally Bioavailable BCL6 BTB Inhibitor."
Assay data:38 Active, 3 Activity ≤ 1 nM, 38 Activity ≤ 1 µM, 50 Tested
SummaryCompounds, ActiveCompounds, activity ≤ 1 µMPubMed CitationRelated BioAssays by DepositorRelated BioAssays by Target
Surface Plasmon Resonance (SPR) assay from Article : "Discovery of OICR12694: A Novel, Potent, Selective, and Orally Bioavailable BCL6 BTB Inhibitor."
Assay data:38 Active, 3 Activity ≤ 1 nM, 37 Activity ≤ 1 µM, 52 Tested
Filters: Manage Filters
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on